List of APIs/Active Pharmaceutical Ingredients Companies in United States - 84

Alchem Laboratories is a pharmaceutical company that specializes in custom organic synthesis, cGMP manufacturing, and analytical services.

We are the pioneers of allergy solutions. Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with respiratory allergies, more than 200 million people have some sort of food allergy, and more than 100 million children are living with allergic rhinitis. These numbers are only expected to increase, and as a result, the need for allergy solutions is ever-growing. For more than a 100 years, ALK has been at the forefront of long-term allergy treatment. Building on our strong heritage, we are now stepping into the next 100 years with a mission to help even more people, with more solutions, more efficiently. We call it Allergy+. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people's lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more, for research use, drug discovery and diagnostic use. We also manufacture custom Peptide based starting materials for GMP applications. As a trusted and long-standing provider to the biopharmaceutical and diagnostic industries, academia, and governmental institutions, we aim to empower the scientific community in their endeavors to elucidate diseases and enhance health and well-being, through our quality proteomic products and services. Our team of experts strive for excellence with honesty and transparency on behalf of our customers. AnaSpec established in 1993 is certified to ISO 9001:2015.

Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc (www.rkpharmainc.com), is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full suite of R&D, QA, QC, and Manufacturing Services. This facilitates a continuous real-time exchange of information, ideas, and data while eliminating redundancies and waste. Our managing partners have over 60 years worth of experience in the pharmaceutical world, encompassing small, mid and large pharmaceutical companies throughout the world. Our Mission is to develop, manufacture, and deliver API’s, with superior quality and regulatory support, at competitive costs.

API Pharmatech is focused on delivering Quality therapeutic products, satisfying Regulatory and Statutory necessities thereby, ensuring safety and purity to its products. We indulged in developing and manufacturing generic and innovative APIs and FDFs. Well capable of resources and expertise to pull out an API from development to commercial scale manufacturing, fulfilling all the required statutory regulations and inspections and involving in the development, manufacturing and marketing of the drug. API Pharmatech constantly updates its knowledge and identifies niche and complex APIs and FDFs which are technologically challenged.

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

A devision of ATTWILL Vascular Technologies, Attwill Medical Solutions purchased the assets of Anteco Pharma facility In 2017. Attwill Medical Solutions specializes in the lyophilization and related processing of pharmaceutical intermediates, medical devices and specialty food and nutritional ingredients. ATTWILL operates a fully integrated commercialization business within a 36,500 square foot facility that includes R&D laboratories, piloting facilities and seven ISO 7 cleanrooms for manufacturing. Our ISO 13485 2016 manufacturing includes six freeze dryers that are used in the processing of ATTWILL products and in contract manufacturing of products that include pharmaceuticals, drug ingredients, medical devices, and nutraceuticals

AustinPx™, Pharmaceutics and Manufacturing, was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That's where we come in. Our client-centric approach is designed to simplify the complexity of outsourcing and our team of formulation, analytical and manufacturing experts work with you to overcome challenges and identify opportunities to do more, faster. As the inventors of the KinetiSol™ Technology - a next generation amorphous solid dispersion (ASD) technology for poorly soluble APIs - we look to disrupt the ASD industry with its smaller footprint, broader design space, and greener processing solution.

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Ayana Bio leverages cellular technology to produce bioactive ingredients that support health and wellness. Ayana Bio collaborates with global industry leaders in food and beverages, dietary supplements, sports nutrition, animal care, and cosmetics to bring standardized plant and fungal bioactives to market. We provide consumers with confidence in quality and reliability. Ayana Bio has partnered with Ginkgo Bioworks, a synthetic biology platform company that is redesigning the living world to solve some of the globe's growing challenges in health, energy, food, material, and more. Ayana Bio is backed by Viking Global Investors and Cascade Investment to democratize nature's bioactives in a way that is standardized, safe, and sustainably sourced.

We work to find new uses for algae as sustainable, natural ingredients for food colorants and flavors; protein powders for plant-based meat; biostimulants to improve yield and quality in vertical farming and growth media to move cell-based food from the laboratory to the table. Based at The Plant in Chicago, BYAS has its own laboratories, production units, photobioreactors and access to a large anaerobic digester.

Biolink LifeSciences is a premier contract research organization offering a comprehensive range of services including synthesis, characterization, formulation development, and analytical services for small to large molecules for nearly all dosage forms. Our strength resides with our highly experienced team in synthetic chemistry, analytical method development & validation and formulation development to solve difficult problems.

BioTechnique is a contract manufacturing organization that provides standard and highly-customized cytotoxic and high potency sterile injectable liquid & lyophilized fill-finish services. Our state-of-the-art manufacturing facility is also equipped with a full-scale microbiology lab and offers regulatory affairs, laboratory, and project management support from investigational/clinical all the way through phase IV/commercial. Facility Capabilities: • Sterile injectable manufacturing & packaging for liquid & lyophilized products • Aseptic Vial Filling • Aseptic Lyophilization • Inspection • Formulation • Product Testing • Labeling/Packaging • Stability Storage • Process Design • Full service laboratory • Regulatory affairs support for product filings • Project management Product Capabilities: • Cytotoxics • Highly-Potent Compounds • Monoclonal Antibodies • Antibody Drug Conjugates (ADC) • Suspensions • Inactivated & Attenuated Live Vaccines Filling & Manufacturing Capabilities: • Grade A / ISO 5 Aseptic Filling Suite • 2mL to 100mL vials • 0.2mL to 100mL fill volume • Inline fill volume check weighing • Isolator • 13M2 Lyophilizer • Containment Unloading • Grade A / ISO 5 Capping • Post-Fill / Post-Lyo External Vial Rinse • Single-Use Disposable Manufacturing Train • Vial Inspection & Labeling • ICH Guideline Cold Storage • 2 to 8 ℃ • -20 to -70 ℃ • Stability Chambers & Warehouse Storage • Microbiology & Chemistry Labs

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics'​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.

CAMAG is the world leader in High-Performance Thin-Layer Chromatography. We provide high-end instruments, tools and concepts for TLC/HPTLC. Additionally, we support our clients with training, technical and contract laboratory services. Wherever complex substance mixtures are analyzed (e.g. herbal, environmental or forensic samples), TLC/HPTLC often is an excellent alternative to GC and HPLC. Moreover, it has proven value as a solid quantitative analysis technique in quality assurance of food, pharmaceuticals and other industrial products. Since 1961, CAMAG is dedicated to the development and manufacturing of instruments, software and consumables for all steps of the TLC/HPTLC procedure. Our products are truly Swiss made and have an excellent reputation throughout the world.

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services. With over 40 years of experience and a growing team of over 2,000 experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing.

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

Cardax is developing proprietary astaxanthin therapies for large unmet medical needs where oxidative stress and inflammation play important causative roles. Introduction Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

API Services

LEADING THE SUPPLY OF HIGH QUALITY GENERIC APIs 21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality API's to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection, development, analytical and regulatory services, and strong project management to ensure the highest standards of quality. We are committed to providing our customers with a distinct competitive advantage. Our team of technical, analytical, regulatory and marketing experts can enhance your business by: 1. Advancing your product development; 2. Ensuring the manufacturing facilities we represent maintain a high level of compliance with ever-evolving cGMPs; 3. Collaborating with manufacturers in establishing appropriate protocols and methodologies to prepare a sound and complete DMF; 4. Sourcing APIs from China, India, Germany and the US to provide our customers with the best value; and 5. Advancing Paragraph IV filings through our exclusive API development and supply partnerships.

Drug Discovery Research Service provider company working out of southwestern Suburbs of Chicago (USA) www.chicagodiscoverysolutions.com. It is the mission of Chicago Discovery Solutions LLC (CDS) to find innovative solutions which will facilitate discovery of innovative drugs and truly applicable green technologies. Our core strength in innovative Chemistry, ability to conceive new pharmacophores, lead generation and optimization of lead molecules for ADME and/or toxicity can help companies involved in drug discovery research. Our scientists have an outstanding track record of achievements in heterocyclic and medicinal chemistry.They have the demonstrated success in starting programs by generating pharmacophores and taking the molecules all the way to clinical trial stages. Chicago Discovery Solutions (CDS) facilitates and accelerates Medicinal Chemistry research by making available special building blocks as privileged structures. Our building blocks are carefully selected and assembled in a constantly updated catalogue. Most of these small 'non-planar' structures provide 3 D exit vectors for substitutions which are very useful for medicinal chemists. We are involved in the development of new and more efficient heterogeeous catalysts for C-C coupling (in-house R&D program).

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. CONTRACT PHARMA offers advertising opportunities in our print magazine, Contract Pharma Direct weekly e newsletter and on contractpharma.com. We are the only worldwide print publication focused on Bio/Pharma contract services, delivering a total qualified circulation of 20,013. (VAC audit statement) On Sept. 26-27, 2024 CONTRACT PHARMA will host its 23rd Annual Contracting & Outsourcing Conference & Tabletop Exhibition. This event brings together speakers from the FDA, industry leaders, and expert analysts to discuss issues critical to success for Pharma & Biopharma outsourcing. The one-day Tabletop Exhibition of 160 top contract service providers provides great exposure to outsourcing decision makers. CONTRACT PHARMA's Corporate Capabilities and Contract Services Directory is the largest single source for company profiles and contract services. This standalone print issue showcases the services of Bio/Pharma contract service providers. The Contract Services Directory is also available online at www.contractpharma.com/csd. It's an indispensable guide for contract services in print and online. Every week, thousands of Bio/Pharma outsourcing professionals go to www.contractpharma.com to read current features, find archive stories, and get breaking news and online exclusives. We also e-mail CONTRACT PHARMA DIRECT, our weekly e-newsletter, to more than 20,000 people. CPDirect is filled with the latest news, our most recent articles, and links to our popular annual features and upcoming meetings. Free subscriptions are available on our website. Contact us for more information on how your company can get involved with Contract Pharma.

Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance.

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQ, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products

Double Rainbow is leveraging the critical role of glycans in human biology to bioengineer anew class of glyco-drug conjugates (GDC) and deliver the next generation of precision medicines.

Dr. Reddy's Laboratories is a pharmaceutical company that specializes in pharmaceutical manufacturing and healthcare products.

Eby Pharma offers a gallium nitrate product to reduce both the incidence of lameness and the severity of navicular syndrome and navicular disorders in horses.

Ecovia Renewables Inc. was formed in 2014 as a spin-out company from the University of Michigan. It is our mission to develop and commercialize high-performing biobased ingredients and materials from sustainable processes at the best value for our customers. We do this by having microbial ecosystems work for us. Our suite of Ecovia™ Biopolymers are created from a proprietary fermentation process. They are affordable, biobased, biodegradable, and functional alternatives to conventional acrylate and acrylamide polymers and starch-based biopolymers. Applications range from soil additives for water retention to super-absorbent cores for infant diapers to thickeners for personal care and industrial products, among many others.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Emery Pharma (EP) (emerypharma.com) is a FDA registered/inspected, DEA licensed, and cGMP/GLP compliant full service contract research laboratory specializing in microbiology & cell-biology testing, medicinal chemistry, analytical chemistry, and bio-analytical services. EP is located in Alameda, CA, at the heart of San Francisco Bay area. We have been supporting clients both locally and globally. We have deep expertise in drug development and support clients from early preclinical all the way to Phase 3 clinical program. Our Bioanalytical Chemistry team utilizes the state of the art LCMS-MS instrument to unravel the targeted compounds in blood, plasma, skin, etc- We provide assistance with R&D method development, validation, method transfer and analytical services. Medicinal Chemistry: Our team has expertise in diverse therapeutic areas covers all aspects of medicinal chemistry, from strategic planning to hit evaluation and validation to lead optimization and pre-clinical development. Analytical Separation Chemistry: Utilizing NMR, LC-MS, HPLC, GC-MS. Microbiology: Spectrum of Antibacterial and Antifungal Activity, Biofilm Profiling, Resistance Profiling, Cytotoxicity Testing, Microscopy Services, Tissue Efficacy Modeling

Emtora Biosciences is a life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer. A Phase 1b safety and dosing clinical trial is underway in early stage prostate cancer patients. A pilot efficacy study in Familial Adenomatous Polyposis (FAP) is planned for late 2019.

Entrinsic Bioscience is a biotechnology company that specializes in developing functional ingredients and Active Pharmaceutical Ingredients (APIs) through a proprietary platform centered on amino acid combinations. The company utilizes a biomapping and electrophysiology platform to identify and patent specific amino acid combinations that influence protein regulation and cell signaling. This technology has its origins in research conducted with NASA, aimed at addressing gastrointestinal damage from ionizing radiation during deep space missions. The company offers a range of applications, including products for pulmonary health, digestive health, immune regulation, metabolism, hydration, and skin health. One of its notable products is enterade IBS-D, a non-prescription medical food designed to manage symptoms of IBS-D. Entrinsic collaborates with healthcare providers, academic institutions, and global partners to commercialize its formulations, focusing on science-backed, plant-based solutions that enhance health outcomes.

Infusing Innovation In Everything We Do Looking for hemp-derived CBD ingredients of the highest quality, purity and consistency? Need a proven source for premium bulk and differentiated finished goods, whose mandate to champion innovation, science and compliance leads the field? Explore how the beneficial properties of CBD can enhance your product’s impact and value — in food and beverage, creams and other topicals, pet products and more. Trust a genuine industry pioneer. Partner with GenCanna. Since our inception in 2014, GenCanna has remained at the vanguard of today’s now booming CBD industry, because our influential founders helped create it. Literally. Vetted, tested and proven over time, this makes us your smartest, surest choice in a full-service CBD partner. Our roots extend back to the earliest days of cannabis legalization and reform. GenCanna helped lead the introduction of Kentucky’s groundbreaking 2014 Hemp Pilot Program. We continue spearheading regulatory initiatives that open and accelerate industry growth. In short, GenCanna has remained at the heart of it all, earning the highest industry certifications, product validations and compliance accreditations to this day. Our scalable, premium-quality derivatives and differentiated finished goods bear witness to GenCanna’s unbridled commitment to excellence: • High-Quality Cannabinoid Isolates and Distillates • Premium Bulk Broad-Spectrum and Full-Spectrum Ingredients • Water-Soluble Liquids and Soluble Powders • Reserve Oils and Bottled Custom Oil Drops • Superior Custom Formulations: -Gummies -Capsules, soft gels, tablets, and other supplement form factors -Food and beverages -Broad range of cosmetics and topicals -Health and wellbeing topicals -Pet products • Turnkey Private Label Programs • White Label Products … you name it, we’ll infuse it! Ready to achieve the next level in CBD success? RELIABLE. INNOVATIVE. GENCANNA. Premium CBD ingredients that formulate profitability for you.

Numotizine is a healthcare company that specializes in producing a patented poultice for external medical use.

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.

For over 30 years, Interchem has been successfully locating sources of fine chemicals, intermediates, bulk actives, and sophisticated next generation compounds from all over the world. With global capabilities, we are able to bring together materials and producers to supply almost any product. Through combining the expansive range of chemistries at our disposal with our in-house technical and regulatory expertise, we are able to successfully handle your diverse requirements in a quick and reliable manner. In addition, our project management and tracking systems ensure high levels of customer service at all times. Interchem prides itself on supplying a service that leverages professional sourcing with contracting expertise, technical assistance, and regulatory support.

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organize our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

K.C. Pharmaceuticals, Inc. is committed in meeting the requirements of the Current Good Manufacturing Practices (CGMP) laid out in the Code of Federal Regulations (CFR) issued by the US Food and Drug Administration (FDA). We are devoted in producing finished pharmaceuticals and medical devices that uphold high quality standards in today's consumer market. As part of our ongoing efforts in maintaining compliance, we have been keen in implementing many systems and procedures designed to improve product quality and ensure customer satisfaction. Since our manufacturing paradigm is "Building Quality Into Products," we have various internal quality control and quality assurance checkpoints through audits, inspections, reviews, and tests to guarantee that all quality requirements have been met.

Kemin Industries is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human health, food safety and protection of the global food supply chain. Kemin ingredients offer solutions across various industries including animal health, nutraceuticals, pet food, food technologies, crop technologies, textiles, aquaculture and animal vaccines. Serving customers in more than 120 countries, Kemin works each day to provide ingredients that feed a growing population and is committed to the quality, safety and efficacy of food, feed and health-related products. Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 3,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, India, Italy, Russia, San Marino, Singapore, South Africa and the United States.

Leading Pharma, LLC is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Our products are available in various dosage forms across many therapeutic areas under the Leading label. Product and Customer Related Inquiries – MEDICAL INFORMATION · Report Adverse Events / Side Effects · Report Product Complaints · Submit Medical Inquiries · Report Product Overdose and Poisoning Please contact us in the given details. By Phone: (844)-740-7500 By Fax: (973)-276-9656 By Email: micc_leadingpharma@mitoconbiopharma.com

LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical industry. We secure and optimize your supply chain with our extensive qualified API partner network, global drug product development and manufacturing facilities, and regulatory and market intelligence services delivering customized solutions that get your products to market faster. Full-service, expert support that accelerates the new product pathway. Now that’s smart. • Established in 2005 • ISO 9001-2015 QMS certified company • CGMP systems in accordance with ICH Q7 • Main business segments: R&D / Biotech / CDMO / Specialty Pharma Companies, New Drug Delivery Technologies (NDA/505b2) – with heavy concentration on injectables, transdermal, nasal, inhalation, ophthalmic & sublingual drug deliveries Our products originate from our API manufacturing partner sites who are approved by the leading regulatory authorities, such as the US-FDA, EDQM, TGA, UK-MHRA, PMDA etc. LGM’s industry experience enables us to support our clients throughout the entire pathway of drug development, from discovery through commercial production. Based on the scale and scope of development projects with which we are involved, we are able to provide our customers with a seasoned perspective and valuable market insight. LGM Pharma has enhanced its position as a leading supplier of newly approved APIs, including full technical documentation and regulatory support. Our Clients: At LGM Pharma, our clients’ needs are our top priority, and we support our client base consisting of a diverse array of pharma companies, including: • Contract Research, Development & Manufacturing Organizations • Specialty Pharma and Novel Drug Delivery Systems • R&D & Biotech Companies • Generic Pharma Companies • Chemical Catalog Companies • OTC & Private Label Manufacturers • Academic & Government Laboratories • Pharmacy Compounding Industry

LipoSeuticals is a specialty pharmaceutical company that engages in the development, manufacturing and commercialization of parenteral drug products.

Welcome to Lyndra Therapeutics: Medicine, reinvented Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible. Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication. Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA. Core purpose: reinvent medicine for a healthier world Core values: value every voice; resilient to the core; I contribute, we deliver

Matrix Biomed, Inc. is a biopharmaceutical company focused on delivering gene-based therapeutics. Gene-based therapeutics are directed to address both the dysregulation of multiple genes as well as their interactions in gene regulatory networks. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state. Currently, Matrix Biomed, Inc. gene-based therapeutics are directed to therapies and drug products to make cancer treatment more manageable and successful through the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy while targeting the master genes responsible for cancer growth and development, hypoxia inducible factor -1 (HIF-1) and hypoxia inducible factor-2 (HIF2).

Metrics Contract Services is a North Carolina-based CDMO that offers services such as formulation development, analytical testing, and drug manufacturing for the pharmaceutical industry.

NeoTherma Oncology is answering the world's call for more effective, more humane cancer treatment. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treament for deep, solid tumors that is expected to increase the effectiveness of current cancer treatments, while minimizing the harshest effects of chemotherapy and radiation. NeoTherma's cutting edge non-invasive technology, seamless integration into established MRI treatment suites, and clinical development strategy set us apart as industry innovators with the vision to reimagine cancer treatment. Please see our website for more information and NTO's exciting news (http://neothermaoncology.com/)!

NEXGEL Advanced Hydrogel Solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and FDA-approved for the Hospital Wound Care market, and is now being deployed against Consumer OTC, Rx, Medical Device and Cosmetic applications.

Nissan Chemical America Corporation is a division of Nissan Chemical Corporation, founded in 1887 as the first chemical fertilizer manufacturer in Japan. A forerunner in chemical innovations for nearly 130 years, Nissan Chemical currently manufactures products for the chemical, agrochemical, and pharmaceutical industries and is a market leader in the production of nanoparticles for the automotive, coatings, electronics, and oil and gas industries.

Norac Pharma is a preferred California-based API contract research and manufacturing organization offering close partnership in bringing drugs to market through excellence in process development, analytical services and cGMP manufacture of Active Pharmaceutical Ingredients (API's) & intermediates. With over 40 years of API experience, including expertise in Controlled Substances and Potent Compounds, Norac Pharma delivers timely, efficient, and regulatory-compliant service in support of your API development needs. Our excellent track record in successful project delivery along with our extensive experience justifies your confidence in our ability to deliver, irrespective of target chemistry complexity. Exceptional Chemistry - Creative Solutions

Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III

Optimeos Life Sciences is pioneering a novel targeted gene delivery approach to advance medical treatment and patient care.

A life sciences company modernizing the way medicines are taken. Our mission is to improve patient outcomes through our next generation therapeutic delivery system, the Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. With our proprietary manufacturing processes and state of the art cGMP-compliant facility in the U.S., we have developed our first product candidate, ORAVEXX™, a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. We are empowering the medical community by partnering with leading research institutions and physicians to support multiple FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to determine the safety and efficacy of CBD for the management of pain and inflammation.

Our mission is to combat dysbiosis* in the human body. To that end, we aim to commercialize antimicrobial peptide therapies to safely restore balance to the gut's microbial flora and overcoming disease. P4 Microbiome was founded by Johns Hopkins University professors Phillip Phan and Jay Pasricha. The company took over the clinical development of P4M01 from the US Army in February of 2020. Together they recognized the immense potential of this discovery, not only for oral health, but also for solving dysbiosis in the GI tract. Beginning with our gingivitis indication, we will work our way down the gastrointestinal (GI) tract, addressing conditions including small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) by correcting the underlying dysbiosis that drives pathology. *Dysbiosis: A change in the microbial composition, especially in the GI tract, that causes imbalance between beneficial and potentially pathogenic bacteria.

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com

Personal Cell Sciences is a Life Sciences company that specializes in developing and distributing personalized Adipose Derived Stem Cell based anti-aging, topical skin care products using individual's own stem cells.

Phythera Therapeutics, Inc. was started to test, develop and improve promising small molecule-based drugs for oncology and inflammation markets. Many small bioactive phyto-molecules used in biomedicine have been derived from plants (hence –Phythera Therapeutics). The cocktail of drugs is expected to be better than one molecule for managing complex diseases with no available treatments. The only medicine which can manage HIV is a cocktail of drugs. We have something of the same magnitude but for oncology, which is viewed as “one drug- one IND” by US FDA. We see the potential of drugs carrying many small bioactive molecules to substantially improve the treatment of cancer, either as an auxiliary or even as the main treatment method. The same is true for inflammation. Optimizing and improving these small molecules to maximize their efficacy to combat metastatic cancers, and converting them into potent and robust treatments of untreatable conditions like metastatic cancer and persistent inflammation is Phythera’s main overarching goal. We leverage our expertise in 3D cell biology and transcriptomics to test the small molecule compounds to define and improve their efficacy in 3D tissue model systems, either as a single compound or as a combination of several most potent small molecule drugs. The team’s proven deep expertise in stem cell biology enables us to study the impact of our candidate molecules on the most elusive and most malignant cancer stem cells and develop drug combinations, optimized for a specific disease. Last but not least, our team has a strong interest in regenerative medicine approaches for inducing tissue regeneration and improving tissue homeostasis, the key to wellness and enduring health. Small molecule compounds derived from plants possess many of the properties promoting tissue regeneration and modulating homeostasis in tissue. Enhancing these properties and converting them into new treatments is Phythera’s 2nd overarching goal.

Qualicaps manufactures empty two-piece capsules (gelatin and hypromellose) and encapsulation equipment under cGMP regulations for use by pharmaceutical, OTC and dietary-supplement manufacturers.

Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Regis is privately owned and operated and has been in business in the Chicagoland area since 1956.

RES Group Inc, an MIT spin-off and a pioneer in QSP (Quantitative Systems Pharmacology) modeling since 2001, is dedicated to accelerating and de-risking drug development. Utilizing mechanistic QSP modeling, we offer a range of services including First-in-Human (FIH) dose projections for IND applications, toxicity projections for regulatory submissions, and support for early-stage drug development. With a track record of successfully collaborating on over 100 new drug developments, we have earned the trust of biotech and pharmaceutical companies alike, as demonstrated by the following examples: Our MIDD (Model Informed Drug Development) approach for Takeda's application for ultra-rare blood clotting disorder was recently approved by FDA: November 9, 2023 Takeda's ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP). Our human dose projection was recently accepted in the IND clearance in treating Duchenne muscular dystrophy: November 14, 2023 Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003.

Salvona Technologies LLC is focused on manufacturing proprietary advanced encapsulation systems that modify the way functional and active ingredients are being delivered. These systems are used to formulate innovative and highly functional products with unique features, including long-lasting release, triggered release, and targeted delivery. The encapsulation technologies are designed to address production and application issues, such as stability of raw materials, formulation practicality, environmental and safety concerns, and user compliance. Salvona has established an umbrella of intellectual property covering its broad technology platforms that provides the company with the freedom to operate and apply these technologies in various markets including consumer health care, dermatology, pharmaceuticals, cosmetics, oral hygiene, and general consumer care. Salvona’s patent portfolio covers both the compositions and applications of its technology platforms. Since its founding, the company has applied for nearly 100 patents. Salvona is privately owned and operates in partnership with ZSCHIMMER & SCHWARZ CHEMIE GmbH.

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients' lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

SkinAxis is a biotechnology company that provides multicellular skin equivalent systems that reproduce the physiological properties of human skin tissues. These models represent the response of human skin to drug and active ingredient treatment more accurately then animal models. SkinAxis multicellular three-dimensional tissues can be customized using cell types engineered to specifically express gene reporter systems. These advanced models allow the faster, more sensitive, and more accurate assessment of the preclinical activity profile of drugs and active compounds. All products by SkinAxis are made in Inited States of America We seek to provide and develop solutions for cosmetic, biotechnology, pharmaceutical, chemical and diagnostic companies and academic laboratories interested in active ingredient testing and drug discovery

Headquartered in Rancho Cordova, Calif., SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. SK pharmteco is comprised of six companies: SK Biotek Korea, SK Biotek Ireland, AMPAC Fine Chemicals, AMPAC Analytical Laboratories in the U.S., Yposkesi and the Center for Breakthrough Medicines.

Snapdragon Chemistry is led by world-class scientists who have made many of the key advances in continuous flow chemistry over the past decade. We provide sophisticated thought partnership and services that enable our clients to harness the advantages of continuous flow chemistry in order to discover more effective medicines and other advanced organic materials, accelerate development, and optimize manufacturing. Tim Jamison, a Professor at MIT’s chemistry department, and Aaron Beeler, an Assistant Professor at Boston University, co-founded Snapdragon Chemistry based on two key revolutionary beliefs: (1) Continuous flow chemistry should be applied throughout the entire discovery >> development >> manufacturing value chain to gain the technology’s optimal benefits. (2) Companies need a sophisticated partner that provides end-to-end services to help them implement effective continuous flow solutions. That is why our company is scientifically-led with a core ethos of unrelenting focus on delivering impact for our clients.

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our proprietary drugs offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.

Underground API-Bearing Plants

Founded in 2004, Sundia MediTech Company, Ltd. is a leading pre-clinical contract research organization (CRO) providing a comprehensive and integrated portfolio of high-quality drug discovery and development services. Sundia's experienced R&D and international management team possess extensive experience across the fields of chemistry (custom synthesis, library design and synthesis), medicinal chemistry, biology (in vitro and in vivo), DMPK, pre-clinical studies, as well as pharmaceutical development (process research and development, API manufacturing, pre-formulation and formulation, analytical as well as QA/QC, CMC and IND filing) services. Sundia's primary research facilities, which include standard and kilo-labs, an animal facility, a pilot plant and other supporting facilities, are located in Shanghai (Zhangjiang Hi-Tech Park), Shijiazhuang and Taicang. For more information, please visit us at www.sundia.com or email us at info@sundia.com.

Sunrise Pharma is a premier provider of safe and affordable generic medicines. Sunrise was founded and is based in the United States. Our products appear in various dosage forms across multiple therapeutic areas. We market products to all pharmaceutical channels including local and national retailers, wholesalers, distributors, health systems, and government. We understand the role of medicine in our society and we are wholly committed to supplying top notch quality products to the US pharmaceutical market. Our aim is to provide a diverse portfolio of safe and affordable generic medications to millions of patients to lead a happier and healthier life.

A new treatment for cancer

TEDOR Pharma Services is a science-driven Contract, testing, Drug Development, and Manufacturing Organization (CDMO). partnering with your team to provide solutions and services for analytical testing; drug dosage development; clinical supply, packaging, distribution; and commercial manufacturing. DEA-scheduled products I-V; high potency; powder biologics; small manufacturing batches and orphan drugs for life science customers. TEDOR has helped customers meet their project timelines, achieve regulatory approvals, and solve formulation challenges. TEDOR Pharma employs skilled and specialized experts that support a wide range of capabilities that include: •Drug Product Development • Analytical Testing • Quality Assurance • Legal Compliance • Regulatory Filing • cGMP Manufacturing • Commercialization Our dynamic work environment provides a great opportunity to learn and grow professionally. We offer competitive wages and benefits, and our employees have the opportunity to drive innovative technologies, setting industry trends. TEDOR is an Equal Opportunity Employer.

Contract research organization specializing in solid-state chemistry. The scientists at Triclinic Labs have the proven experience to help you with the most challenging chemical development, solid-form screening and selection, and intellectual property issues. With our expert organic, physical, and analytical chemistry capabilities we can maximize your development and market and franchise potential. Whether you require rapid materials characterization, IP support during patent prosecution or litigation, solid-form development, or chemical troubleshooting assistance with your pharmaceutical or fine chemical, we have the instrumentation and scientific knowledge to help you reach your goals quickly, thoroughly, and cost effectively. We specialize in: - Solid form screening and development - Crystallization Method Development - Amorphous Material Development - Analytical Method Development, Validation, Release testing - cGMP Materials Characterization - Contaminant, Counterfeit, and Product Failure Analysis - Chemical Intellectual Property Support (Patent Prosecution and Litigation)

Turn Therapeutics® is a concept to approval pharmaceutical and medical device organization dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics® was founded with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. Through research and development, we have continued to uncover additional disease areas that our technology will serve. Our core mission is to leverage our expertise in drug delivery to create disruptive products for high need indications.

The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

YARAL Pharma Inc. is the US subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they're cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service.

Zystein offers alternativehealthcare products made only from all-natural materials. They also offer reagents that canencapsulateactive ingredients, drugs, and vaccines.